Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAEK-VAC-HerBy in Advanced Cancer
NCT04246671Phase 1Completed
- Sponsor
- Bavarian Nordic
- Start
- Aug 2020
- Primary completion
- Feb 2024
- Modality
- Prophylactic Vaccines, Viral Vectors, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAEK-VAC-HerBy in chordoma and HER2-positive breast cancer (6 arms), sponsored by Bavarian Nordic. Primary endpoint: Dose Limiting Toxicity at 30 days. Started Aug 2020; status: completed.
02
Drugs
TAEK-VAC-HerBy
03
Conditions
chordomaHER2-positive breast cancer
Beyond the preview
Go deeper on NCT04246671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246671.